News | April 12, 2026
C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio
The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions
The event also featured discussions on emerging trends in joint replacement surgery
The collaboration brings together AIG Hospitals’ high-volume clinical expertise, advanced innovation capabilities, and growing artificial intelligence-led healthcare initiatives
Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Subscribe To Our Newsletter & Stay Updated
